Covacta Actemra Covid 19 Pneumonia Study
Research payments
$9,254,473
Through program year 2022, $9,254,473 in research payments was reported against Covacta Actemra Covid 19 Pneumonia Study, across 518 payments.
- Paid by (largest first)
- Roche Products Limited; F. Hoffmann-La Roche AG
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2022 | Research | $46,321 | 4 |
| 2021 | Research | $1,922,898 | 197 |
| 2020 | Research | $7,285,254 | 317 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Ivan Rosas Boston, MA Named on 158 payments
- Daniel Skiest Springfield, MA Named on 52 payments
- Krish Patel Seattle, WA Named on 23 payments
- Julia Garcia-Diaz New Orleans, LA Named on 22 payments
- Michael Waters Chula Vista, CA Named on 21 payments
- Mariam Aziz Chicago, IL Named on 14 payments
- Bradley Hunter Salt Lake City, UT Named on 14 payments
- David De La Zerda San Diego, CA Named on 14 payments
- Atul Malhotra La Jolla, CA Named on 13 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.